Japan Halts Use of Pfizer and sanofi Vaccines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Japan Halts Use of Pfizer and sanofi Vaccines


ePT--the Electronic Newsletter of Pharmaceutical Technology

Japan suspended the use of two pediatric vaccines, one made by Pfizer and one by sanofi, following the deaths of four children in three days. The deaths occurred shortly after vaccination with Pfizer’s Prevenar vaccine (known as Prevnar in the United States) and sanofi’s ActHIB vaccine. Although a panel of experts at Japan’s Health Ministry have found no link between the deaths and vaccination, the suspension will remain in place while further studies are conducted.

Other national regulatory agencies are aware of the situation. In Hong Kong, the Department of Health said in a statement that it has “no record of untoward event report[s] associated with Prevenar, but we will inform all medical practitioners of the Japanese incident and request them to bring up any anomaly detected." sanofi’s vaccine is not used in Hong Kong, but both are widely used in the US. According to Reuters, FDA is monitoring the safety of both vaccines, but has not observed any safety concenrs in the US.

This is not the first time that Prevenar has faced safety suspicions. In 2009, a batch of Prevenar was pulled from the market in the Netherlands following the deaths of three infants after vaccination. In February 2010, however, it was announced that there was no link between the deaths and vaccination.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here